A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
Completed · Phase 1 · NCT06946524
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $705,286
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 59
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug)
- Dates
- Started 2025-05-08; completion 2025-11-25
- Results posted
- Not yet
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.
From ClinicalTrials.gov, last updated 2025-12-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $705,286 in research payments for this study in 2025 (9 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Altasciences Professional $705,286
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.